By targeting at multiple pathways or events, such as mammalian target of rapamycin, cell cycle, inflammation, glucose metabolism, angiogenesis, and cancer stem cells, metformin plays its possible anti-cancer role; among them, the AMPK activation is believed to mediate the most effects of metformin [28, 29]. Here, MTOR is linked to cancer.